Expression of CD44, PCNA and E-cadherin in Pterygium Tissue

Pterygium Clinical Trial

Official title:

Expression of CD44, PCNA and E-cadherin in Pterygium Tissue

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06042296
• Other study ID #: BAUNHYILDIRIM-1
• Status: Not yet recruiting
• Start date: October 2023
• Est. completion date: January 2024

Study information

• Verified date: September 2023
• Source: Balikesir University
• Contact: HÜMEYRA YILDIRIM
• Phone: 05305244841
• Email: balikesirhumeyra[@]gmail.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Purpose: Pterygium is a common ocular surface disease defined by fibrovascular conjunctival growth extending onto the cornea. Its pathogenesis remains unclear. In severe cases, it may extend into the central cornea, inducing irregular corneal astigmatism and causing loss of vision. CD44( phagocytic glycoprotein-1 ) is involved in the organization of certain cellular processes, for instance, cell adhesion, division, and migration, by binding with its main ligand, hyaluronic acid. Proliferating cell nuclear antigen (PCNA) is a proliferation marker in the nucleus. E-cadherin is a calcium-dependent transmembrane glycoprotein that plays a significant role in the protection of tissue integrity and cell-to-cell adhesion. This study aimed to determine the role of CD44, proliferating cell nuclear antigen (PCNA), and E-cadherin in pterygium formation and recurrence.

Description:

Methods:60 patients with pterygium will be enrolled in the study and conjunctival samples will be collected from 30 patients to form the control group. CD44, PCNA and E-cadherin expressions in surgically removed pterygium will be compared with tissue samples from normal control group. IBM SPSS (statistical software) version 26.0 will be used for statistical analyses.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: January 2024
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria: patient with pterygium - Exclusion Criteria: patient with pseudopterygium -

Related Conditions & MeSH terms

• Pterygium

Intervention

Other:
• Expression of CD44, E-cadherin and PCNA
The investigators use primary antibodies against CD44 (1:50 dilution) and E-cadherin (1:200 dilution), and a human monoclonal antibody against PCNA (1:100 dilution) for antigen retrieval. Histopathological and immunohistochemical staining findings will be reported using a Nikon light microscope and an image analysis system (Nikon Instruments Europe BV)

Locations

Country	Name	City	State
Turkey	Hümeyra Yildirim	Balikesir

Sponsors (1)

Lead Sponsor	Collaborator
Balikesir University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Immunohistochemistry	Thin sections will be taken from paraffin embedded tissue samples and placed on barcode glass slides After deparaffinization and rehydration, the sections will be subjected to histopathological evaluation using hematoxylin and eosin staining.We use primary antibodies against CD44 (1:50 dilution) and E-cadherin (1:200 dilution), and a human monoclonal antibody against PCNA (1:100 dilution) for antigen retrieval	up to three weeks after pterygium surgery